The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component

Journal of Neuroscience

Volumn 23, Issue 6, 2003, Pages 2086-2092

  Klunk, William E ^a,c   Wang, Yanming ^b   Huang, Guo feng ^b   Debnath, Manik L ^a   Holt, Daniel P ^b   Shao, Li ^a   Hamilton, Ronald L ^b   Ikonomovic, Milos D ^b   DeKosky, Steven T ^b   Mathis, Chester A ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; Benzothiazole; Binding; Neurofibrillarytangles; Neuroimaging; PET; Plaques; Positron emission tomography; Postmortem; Thioflavin T

Indexed keywords

2 (4' METHYLAMINOPHENYL)BENZOTHIAZOLE; AMYLOID; BENZOTHIAZOLE; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BETA SHEET; BRAIN HOMOGENATE; BRAIN MAPPING; COMPLEX FORMATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; NEUROFIBRILLARY TANGLE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TARGET CELL; TISSUE SPECIFICITY; WHITE MATTER;

EID: 0037444535     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-06-02086.2003     Document Type: Article

References (29)

1. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919.
2. Bennett JP, Yamamura HI (1985) Neurotransmitter, hormone, or drug receptor binding methods. In: Neurotransmitter receptor binding (Yamamura HI, Enna SJ, Kuhar MJ, eds), pp 61-89. New York: Raven.
3. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
4. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-706.
5. Goedert M, Spillantini MG (2000) Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. Biochim Biophys Acta 1502:110-121.
6. Golde TE, Eckman CB, Younkin SG (2000) Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 1502:172-187.
7. Hardy J (1992) An "anatomical cascade hypothesis" for Alzheimer's disease. Trends Neurosci 15:200-201.
8. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12:383-388.
9. Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M (1998) Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat Neurosci 1:355-358.
10. Jackson M, Lennox G, Lowe J (1996) Motor neurone disease-inclusion dementia. Neurodegeneration 5:339-350.
11. Joachim CL, Morris JH, Selkoe DJ (1989) Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 135:309-319.
12. Kirschner DA, Abraham C, Selkoe DJ (1986) X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc Natl Acad Sci USA 83:503-507.
13. Klunk WE, (1998) Biological markers of Alzheimer's disease. Neurobiol Aging 19:145-147.
14. Klunk WE, Debnath ML, Pettegrew JW (1994) Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 15:691-698.
15. Klunk WE, Wang Y, Huang G-F, Debnath ML, Holt DP, Mathis CA (2001) Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 69:1471-1484.
16. LeVine H (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2:404-410.
17. Lopez OL, Becker JT, Klunk WE, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Cidis-Meltzer C, Wisniewski S, Kamboh MI, DeKosky ST (2000) Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades. I. Neurology 55:1854-1862.
18. Mann DM (1998) Dementia of frontal type and dementias with subcortical gliosis. Brain Pathol 8:325-338.
19. Mann DM, Iwatsubo T, Snowden JS (1996) A typical amyloid (A beta) deposition in the cerebellum in Alzheimer's disease: an immunohistochemical study using end-specific A beta monoclonal antibodies. Acta Neuropathol 91:647-653.
20. Mathis CA, Bacskai BJ, Kajdasz ST, Mclellan ME, Frosch MP, Hyman BT, Holt DP, Wang Y, Huang G-F, Debnath ML, Klunk WE (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12:295-298.
21. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113-1124.
22. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479-486.
23. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1:345-347.
24. Olson RE, Copeland RA, Seiffert D (2001) Progress towards testing the amyloid hypothesis: inhibitors of APP processing. Curr Opin Drug Discov Devel 4:390-401.
25. Roth BL, Ernsberger P, Steinberg SA, Rao S, Rauser L, Savage J, Hufeisen S, Berridge MS, Muzic RF Jr (2001) The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HHT1A receptor. Psychopharmacology 157:111-114.
26. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841.
27. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
28. Styren SD, Hamilton RL, Styren GC, Klunk WE (2000) X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 48:1223-1232.
29. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y (1989) Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol 77:314-319.